In This Section

Program

Please Note: All session times for the AACR Virtual Meeting: Sarcomas are U.S. Eastern Daylight Time (EDT).

MondayJune 282021 

Welcome and Keynote Address
11-11:35 a.m.   

Keynote Address 
Sandra D’Angelo, Memorial Sloan Kettering Cancer Center, New York, New York

Break 
11:35-11:45 a.m. 
Plenary Session 1: Model Systems 
11:45 a.m.-1:10 p.m. 

Sarcoma patient-derived tumor organoids to investigate tumor  heterogeneity and drug responses
Alice Soragni, University California Los Angeles, Los Angeles, California

Zebrafish modeling of pediatric sarcoma
Genevieve Kendall, Nationwide Children’s Hospital, Columbus, Ohio

Development of a phenotypically diverse model of soft tissue sarcoma to identify key drivers of sarcoma tumorigenesis
Janai Carr-Ascher, University California Davis, Sacramento, California

Title to be announced
Angela Hirbe, Washington University in St. Louis, St. Louis, Missouri

Panel Discussion 

Break  
1:10-1:30 p.m.  
Plenary session 2: Signaling
1:30–2:55 p.m.   

Targeting fusion dependent molecular pathways in CIC-rearranged sarcoma
Ross Okimoto, University of California San Francisco, San Francisco, California 

Targeting cell cycle dysregulation in GIST
Inga-Marie Schaefer, Brigham and Women’s Hospital, Boston, Massachusetts

Profiling the osteosarcoma microenvironment to identify context – specific therapeutic targets
Troy McEachron, National Institutes of Health, Bethesda, Maryland

An essential requirement for amino acid activation of mTORC1 underlies mTOR inhibitor dependence in PAX3-FOXO1 rhabdomyosarcoma
Amit Sabnis, University California San Francisco, San Francisco, California

Panel Discussion

Closing Remarks for the day
2:55-3 p.m. 

TuesdayJune 29, 2021 

Keynote Address 
11-11:35 a.m.   

Keynote Address
Ryan Roberts, Nationwide Children’s Hospital, Columbus, Ohio

Break 
11:35-11:45 a.m. 
Plenary Session 3: Immunotherapy 
11:45 A.M.-1:10 p.m. 

Title to be announced
Robbie Majzner, Stanford University, Stanford, California

Developing Th1 vaccines to prevent relapse in liposarcoma
Laura Riolobos, University of Washington, Seattle, Washington

Modulating tumor milieu to enhance sarcoma immunotherapy
Alex Huang, Case Western Reserve University, Cleveland, OHhio

Title to be announced
Emily Keung, The University of Texas MD Anderson Cancer Center, Houston, Texas

Panel Discussion 

Break  
1:10-1:30 p.m.  
Plenary session 4: Gene Regulation 
1:30 p.m.–2:55 p.m.  

Ewing sarcoma: An enhancer disease with widespread epigenetic heterogeneity
Eleni Tomazou, Children’s Cancer Research Institute, St. Ann Kinderkrebsforschung, Vienna, Austria 

Phasing R-loops in and out by FET proteins and their fusions
Jacob Schwartz, University of Arizona, Tucson, Arizona

Epigenetic determinants of tumor heterogeneity in Synovial Sarcoma
Nicolo Riggi, UNIL- Université de Lausanne, Switzerland

When a mutation profoundly alters chromatin dynamics and modulates oncogene regulation
Didier Surdez, Curie Institute, Paris, France

Panel Discussion

Closing Remarks 
2:55-3 p.m.